hCG_2040054 inhibitors represent a chemical class designed to interact with the structural or functional components of human chorionic gonadotropin (hCG) or its related pathways. Human chorionic gonadotropin is a glycoprotein hormone composed of an alpha and beta subunit, which plays a critical role in various biological processes. Inhibitors within the hCG_2040054 class are engineered to modulate the molecular activities of hCG, potentially by binding to specific sites on the hCG molecule or by disrupting the interaction of hCG with its receptor. These inhibitors can be small molecules, peptides, or larger compounds that are tailored for high specificity and selectivity toward hCG. The chemical design of such inhibitors is typically focused on achieving strong affinity and ensuring that they interfere with the natural function of hCG by preventing conformational changes or signal transduction.
Structurally, hCG_2040054 inhibitors are often designed based on computational modeling of hCG and its receptor interaction sites. The inhibitors may contain distinct functional groups that mimic or disrupt the natural ligands of hCG. These functional groups can engage in hydrogen bonding, hydrophobic interactions, or ionic interactions with critical residues in the target protein. Chemical modification strategies, such as altering the backbone structure, incorporating non-natural amino acids, or introducing lipophilic moieties, are often employed to enhance the inhibitors' stability, bioavailability, and binding efficiency. Advances in synthetic chemistry and high-throughput screening have enabled the generation of hCG_2040054 inhibitors with varying degrees of potency and selectivity, which makes them valuable tools for studying the underlying molecular mechanisms of hCG-mediated processes.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Inhibits AKT phosphorylation, thereby impeding AKT-mediated signaling which hCG_2040054 may be involved in. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, a kinase involved in cell growth and proliferation that hCG_2040054 may regulate or be regulated by. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAPK, affecting stress response pathways that hCG_2040054 may participate in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK, which is upstream of ERK in the MAPK pathway, potentially affecting hCG_2040054's function in cell signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, altering AKT signaling and other pathways that hCG_2040054 may be involved in. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, modifying the cellular response to stress, which may include the activity of hCG_2040054. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
Inhibits Src family kinases, potentially altering signaling pathways that hCG_2040054 is part of. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Inhibits MEK1/2, blocking the MAPK/ERK pathway and potentially affecting processes regulated by hCG_2040054. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Inhibits PI3K, potentially affecting the PI3K/Akt pathway which hCG_2040054 may be associated with. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
Inhibits CaMKII, potentially altering calcium signaling pathways and processes that involve hCG_2040054. | ||||||